Further analysis of the immune microenvironment showed that high expression of LGALS3 was positively correlated with immune checkpoint gene expression, CCL20, CCR6, and Treg cells in patients with CHI, HBV-HF, or HBV-HCC. Here, LGALS3 is linked to hepatocellular carcinoma.